I have only one concern with your calculations, the $383k loss...

I have only one concern with your calculations, the $383k loss could be a lot more depending on the cost of the on going human and canine trials.

The operating loss was actually $320K, not $383K as the rest was related to investment activities. Previous yearly loss was $1.3mill, pretty much in line with the last quarterly. So it's been that way for the last 15 months, I am not sure why you're suddenly making an assumption that the cost could now be a lot more and a CR needed. Seems like a pure guess to me on no real factual evidence.

The fact that the sp seems to struggle to reach the .01 which was the price per share for the last cr. The sp has not really reacted to any of what appears on the surface announcements

Nature of the beast unfortunately when it comes to speculative bio companies. Share price rarely moves to logic and it's a long-term commitment. Placements are also a given although PAA have shown great control in this area (compared to many others) so this is an immense positive.